ArticleBMC pregnancy and childbirth2026
Evaluation of the APRI score and blood-count-derived inflammatory markers in patients with preeclampsia.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the clinical significance of the Aspartate Aminotransferase to Platelet Ratio Index (APRI) score and blood-count-derived inflammatory markers in patients with preeclampsia. MATERIALS AND
methodsThis retrospective study included pregnant women diagnosed with preeclampsia, gestational hypertension, and healthy controls. Demographic, perinatal, hematological, and biochemical parameters were analyzed. Inflammatory markers, including Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), and APRI score, were compared among the study groups. ROC analysis was performed to assess the diagnostic discriminatory performance of these markers in diagnosing preeclampsia.
resultsThe APRI score was significantly higher in the preeclampsia group compared to the control and gestational hypertension groups (p = 0.004), suggesting potential hepatic involvement in preeclampsia. In contrast, no statistically significant differences were found among the groups for NLR (p = 0.106), MLR (p = 0.593), PLR (p = 0.319), and SII (p = 0.247). Hematological and biochemical analysis revealed that AST, BUN, and creatinine levels were significantly elevated in the preeclampsia group (p < 0.001), consistent with hepatic and renal involvement. However, platelet counts and hemoglobin levels did not show significant differences among the groups. ROC analysis demonstrated that the APRI score had poor diagnostic discriminatory performance (AUC = 0.437, p = 0.128), and similarly, other inflammatory markers, including NLR (AUC = 0.539), MLR (AUC = 0.554), PLR (AUC = 0.552), and SII (AUC = 0.507), also failed to exhibit significant diagnostic accuracy.
conclusionAlthough the APRI score was elevated in preeclamptic patients, ROC analysis indicated poor discriminatory performance, suggesting that APRI does not provide meaningful diagnostic accuracy when used alone. Further prospective studies with larger populations are needed to explore its potential role in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.